Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Humacyte Inc
(NQ:
HUMA
)
4.300
-0.190 (-4.23%)
Streaming Delayed Price
Updated: 3:46 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Humacyte Inc
< Previous
1
2
3
4
5
6
Next >
Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023
September 18, 2023
From
Humacyte, Inc
Via
GlobeNewswire
Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
September 12, 2023
Humacyte Inc (NASDAQ: HUMA) released topline results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair, showing that the HAV had higher rates of patency and...
Via
Benzinga
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
September 12, 2023
Gainers AgileThought, Inc. (NASDAQ: AGIL) shares rose 72.5% to $0.2160 in pre-market trading after declining 12% on Monday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
September 12, 2023
It's time to start the day off with a breakdown of the biggest pre-market stock movers worth watching on Tuesday morning!
Via
InvestorPlace
Humacyte Earnings Preview
August 11, 2023
Via
Benzinga
Recap: Humacyte Q1 Earnings
May 12, 2023
Via
Benzinga
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 12, 2023
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.
Via
Benzinga
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
September 12, 2023
From
Humacyte, Inc
Via
GlobeNewswire
Earnings Outlook For Humacyte
May 11, 2023
Via
Benzinga
Earnings Preview For Humacyte
March 23, 2023
Via
Benzinga
5 Value Stocks In The Healthcare Sector
February 13, 2023
Via
Benzinga
5 Value Stocks In The Healthcare Sector
December 26, 2022
Via
Benzinga
Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET
September 11, 2023
Virtual Webinar to Include Key Opinion Leader Perspectives on the Potential of the HAV in Vascular Trauma Repair
From
Humacyte, Inc
Via
GlobeNewswire
Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference
September 11, 2023
-Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage-
From
Humacyte, Inc
Via
GlobeNewswire
Humacyte's Return on Invested Capital Insights
December 19, 2022
Via
Benzinga
Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
August 16, 2023
The public's scrutiny of Congress members trading stocks and options has intensified as websites and social media increasingly broadcast the disclosed data.
Via
Benzinga
Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
August 15, 2023
U.S. stocks traded lower, with the Dow Jones falling around 300 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
August 14, 2023
Via
Benzinga
Humacyte Second Quarter 2023 Financial Results and Business Update
August 14, 2023
From
Humacyte, Inc
Via
GlobeNewswire
Earnings Scheduled For August 14, 2023
August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
June 22, 2023
Via
Benzinga
Earnings Scheduled For May 12, 2023
May 12, 2023
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter.
Via
Benzinga
Earnings Scheduled For March 24, 2023
March 24, 2023
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely to report earnings for its fourth quarter. • Caledonia Mining (AMEX:CMCL) is projected to report earnings for its fourth...
Via
Benzinga
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
March 24, 2023
From
Humacyte, Inc
Via
GlobeNewswire
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023
March 21, 2023
From
Humacyte, Inc
Via
GlobeNewswire
Humacyte to Present at Upcoming Investor Conferences in March
February 27, 2023
From
Humacyte, Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
February 13, 2023
Via
Benzinga
Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease
January 24, 2023
From
Humacyte, Inc
Via
GlobeNewswire
Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime
December 13, 2022
Thursday, December 15, 2022 @ 8:00 AM ET
From
Humacyte, Inc
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
December 14, 2022
On Wednesday, 115 stocks hit new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.